...
首页> 外文期刊>Journal of inherited metabolic disease >Clinical glycomics for the diagnosis of congenital disorders of glycosylation
【24h】

Clinical glycomics for the diagnosis of congenital disorders of glycosylation

机译:用于诊断糖基化的临床综合症

获取原文
获取原文并翻译 | 示例
           

摘要

Clinical glycomics comprises a spectrum of different analytical methodologies to analyze glycan structures, which provides insights into the mechanisms of glycosylation. Within clinical diagnostics, glycomics serves as a functional readout of genetic variants, and can form a basis for therapy development, as was described for PGM1-CDG. Integration of glycomics with genomics has resulted in the elucidation of previously unknown disorders of glycosylation. namely CCDC115-CDG, TMEM199-CDG, ATP6AP1-CDG, MAN1B1-CDG, and PGM1-CDG. This review provides an introduction into protein glycosylation and presents the different glycomics methodologies ranging from gel electrophoresis to mass spectrometry (MS) and from free glycans to intact glycoproteins. The role of glycomics in the diagnosis of congenital disorders of glycosylation (CDG) is presented, including a diagnostic flow chart and an overview of glycomics data of known CDG subtypes. The review ends with some future perspectives, showing upcoming technologies as system wide mapping of the N- and O-glycoproteome, intact glycoprotein profiling and analysis of sugar metabolism. These new advances will provide additional insights and opportunities to develop personalized therapy. This is especially true for inborn errors of metabolism, which arc amenable to causal therapy, because interventions through supplementation therapy can directly target the pathogenesis at the molecular level.
机译:临床综合症包括分析甘油结构的不同分析方法的光谱,其为糖基化机制提供了洞察力。在临床诊断中,糖类用作遗传变异的功能读数,并且可以形成治疗开发的基础,如PGM1-CDG所述。糖类与基因组学的整合导致阐明先前未知的糖基化疾病。即CCDC115-CDG,TMEM199-CDG,ATP6AP1-CDG,MAN1B1-CDG和PGM1-CDG。该综述提供了蛋白质糖基化的引入,并呈现不同的含量方法,从凝胶电泳到质谱(MS)和游离聚乙烯以完善糖蛋白。综合症在糖糖基化(CDG)先天性疾病诊断中的作用,包括诊断流程图和已知CDG亚型的糖类数据的概述。审查以一些未来的观点结束,将即将到来的技术作为系统广泛映射的N-和O-糖蛋白,完整的糖蛋白分析和糖代谢分析。这些新的进展将提供额外的见解和机会来开发个性化治疗。这对于原始的新陈代谢误差尤其如此,因为通过补充治疗的干预措施可以直接针对分子水平直接靶向发病机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号